

CNS Stimulants





Introduction

- Psychomotor stimulants
 - Cause excitement and euphoria
 - Decrease feeling of fatigue
 - Increase motor activity
- Hallucinogens (psychomimetic drugs)
 - Produce changes in thought patterns and mood



Introduction

- **Psychomotor stimulants**
 - Amphetamine
 - Dextroamphetamine
 - Methylphenidate
 - Caffeine
 - Theophylline
 - Nicotine
 - Cocaine
 - Varenicline
- **Hallucinogens**
 - Lysergic acid diethylamide (LSD)
 - Tetrahydrocannabinol
 - Phencyclidine
- **Nonstimulant drugs for ADHD**
 - Atomoxetine
 - Clonidine
 - Guanfacine
 - Viloxazine




Figure 10.2

Relative potential for physical dependence on commonly abused substances. LSD = lysergic acid diethylamide.



Methylxanthines

- Include **theophylline** (tea); **theobromine** (cocoa); and **caffeine** (coffee, tea, cocoa, chocolates, cola drinks)
- **Mechanism of action**
 - Translocation of extracellular calcium
 - Increase in cAMP and cGMP caused by inhibition of phosphodiesterase
 - Blockade of adenosine receptors



Methylxanthines

- **Actions**
 - **CNS stimulants**
 - Reduces fatigue and increase mental alertness due to stimulation of the cortex and other areas of the brain
 - At very high doses, can produce anxiety and tremor
 - Tolerance to caffeine can develop and withdrawal consists of feelings of fatigue and sedation
 - At high doses, has positive inotropic and chronotropic effects on the heart, can be harmful to angina patients and can trigger premature ventricular contractions
 - Caffeine has a mild diuretic effect increasing urinary output of Na, K, and Cl
 - Methylxanthines stimulate secretion of hydrochloric acid from gastric mucosa, should be avoided in peptic ulcer



Methylxanthines

- Therapeutic uses
 - All methylxanthines relax the smooth muscles of the bronchioles
 - Theophylline was used for asthma but it is being replaced by β 2-agonists and corticosteroids
- Adverse effects
 - Insomnia
 - Anxiety
 - Agitation



Nicotine

- CNS stimulant
- Not used therapeutically (except in smoking cessation therapy)
- Stimulation of sympathetic ganglia increases blood pressure and heart rate
- Particularly harmful in hypertensive patients
- Nicotine induced vasoconstriction can decrease coronary blood flow, adversely affecting a patient with angina
- High doses of nicotine result in central respiratory paralysis and severe hypotension caused by medullary paralysis
- Along with other components of cigarettes like tars and carbon monoxide, nicotine is a risk factor for lung and cardiovascular diseases and cancer



Nicotine





Figure 22.2 Actions of *nicotine* on the CNS.



Nicotine

- Causes dependence that is not easily overcome
- Withdrawal symptoms include irritability, anxiety, restlessness, headaches and insomnia
- Smoking cessation programs that combine pharmacologic and behavioral therapy are the most successful in helping individuals to stop smoking
- Transdermal nicotine patch and nicotine chewing gum can reduce withdrawal symptoms
- Bupropion (Wellbutrin[®], Zyban[®])
 - An antidepressant, can reduce the craving for cigarettes





Nicotine

- Varenicline (Champix®)
 - Partial agonist at neuronal nicotinic acetylcholine receptors in the CNS
 - Produces less euphoric effects than nicotine
 - Useful as an adjunct in the management of smoking cessation in patients with nicotine withdrawal symptoms
 - Varenicline tends to attenuate the rewarding effects of nicotine if a person relapses and uses tobacco
 - Patients should be monitored for suicidal thoughts and mood changes



Cocaine

- Highly addictive
- Drug of abuse
- Classified as schedule II by the US Drug Enforcement agency



Figure 22.5 Cocaine and amphetamine have potential for addiction.



Cocaine

- **Mechanism:**
 - Inhibit reuptake of norepinephrine, serotonin and dopamine into the presynaptic terminals
 - Binds to the monoaminergic reuptake transporters
 - Potentiates and prolongs the CNS and peripheral actions of these monoamines
 - Prolongation of dopaminergic effects in the brain's pleasure system (limbic system) produces the intense euphoria initially
 - Chronic intake of cocaine depletes dopamine causing craving for cocaine that temporarily relieves severe depression



Cocaine

- **Actions:**
 - CNS stimulant, produces euphoria, increases mental awareness, can cause hallucinations
 - At high doses, it causes convulsions, followed by respiratory depression
 - Activates sympathetic nervous system causing tachycardia and hypertension, ability of baroreceptor reflexes to buffer the hypertensive effect may be impaired
 - Hyperthermia: Cocaine is unique among illicit drugs in that death can result also from the drug's ability to cause hyperthermia. Even a small dose of intranasal cocaine impairs sweating and cutaneous vasodilation, perception of thermal discomfort is also decreased



Cocaine

- **Therapeutic uses:**
 - Cocaine has a local anesthetic action that represents its only current therapeutic use
 - Cocaine is applied topically as a local anesthetic during eye, ear, nose, and throat surgery
 - The local anesthetic action of cocaine is due to a block of voltage-activated sodium channels



Cocaine

- **Adverse effects**
 - Anxiety
 - Depression
 - Agitation
 - Seizures
 - Fatal arrhythmias



Amphetamines

- Releases intracellular stores of catecholamines (norepinephrine, serotonin, dopamine)
- Inhibits MAO
- **Dextroamphetamine (similar to amphetamine)**
- **Methamphetamine**
- **Actions**
 - CNS stimulant, increase alertness, reduce fatigue, depress appetite
 - Activate the sympathetic nervous system
- Can cause dependence (limit their use)




Figure 15.6
Mechanism of action of amphetamine.



Amphetamines

- **Therapeutic use:**
- Treatment of hyperactivity in children, attention deficit hyperactivity disorder (ADHD)
- Appetite control
- Narcolepsy (uncontrollable sleepiness during the day)
 - Amphetamine
 - Methylphenidate



Amphetamines

- **Adverse effects**
 - Insomnia
 - Irritability
 - Weakness
 - Palpitations, arrhythmias and hypertension
 - Nausea vomiting, diarrhea
- Contraindicated in hypertension, cardiovascular disease, hyperthyroidism or anyone taking MAO inhibitors




Figure 15.7
Adverse effects of amphetamines
and methylphenidate.



Methylphenidate

- CNS stimulant
- **Mechanism of action:**
 - Children with ADHD may produce weak dopamine signals, which suggests that once-interesting activities provide fewer rewards to these children.
 - Methylphenidate is a dopamine transport inhibitor and may act by increasing dopamine in the synaptic space.
- Used for ADHD in children
- Can cause dependence



Methylphenidate

- **Adverse reactions**
 - Abdominal pain and nausea
 - Anorexia
 - Insomnia, nervousness, and fever
- Methylphenidate can interfere in the metabolism of warfarin, phenytoin, phenobarbital, primidone, and the tricyclic antidepressants



Hallucinogens

- Psychomimetics, drugs that induce altered perceptual states accompanied by visions of bright, colorful changes in the environment and by a plasticity of constantly changing shapes and color
- These drugs impair normal decision-making because they interfere with rational thought



Hallucinogens

- **Lysergic acid diethylamide (LSD)**
 - Serotonin agonist
 - Activation of the sympathetic nervous system occurs causing pupillary dilation, increased blood pressure, piloerection, and increased body temperature
 - Taken orally, low doses of LSD can induce hallucinations with brilliant colors
 - Haloperidol and other neuroleptics can block the hallucinatory action of LSD and quickly abort the syndrome.
- **Adverse effects**
 - Hyperreflexia, nausea, and muscular weakness
 - High doses may produce long-lasting psychotic changes in susceptible individuals



Hallucinogens

- **Tetrahydrocannabinol**
 - Found in marijuana
 - Produce euphoria followed by drowsiness and relaxation
 - Cause hallucinations



Hallucinogens

- Effects include
 - Appetite stimulation
 - Xerostomia
 - Visual hallucinations, delusions
- Adverse effects
 - Adversely affects short-term memory and mental activity
 - Decreases muscle strength and impairs highly skilled motor activity
 - Increased heart rate
 - Decreased blood pressure, and reddening of the conjunctiva
 - At high doses, a toxic psychosis develops



Hallucinogens

- **Phencyclidine**
 - Illegal drug
 - Also known as PCP or angel's dust
 - Inhibits the reuptake of dopamine, 5-HT, and norepinephrine
 - Causes dissociative anesthesia (insensitivity to pain without loss of consciousness) and analgesia
 - Produces numbness of extremities, staggered gait, slurred speech, and muscular rigidity
 - At increased dosages, anesthesia, stupor and coma may result
 - Increased sensitivity to external stimuli results, and the CNS actions may persist for a week
 - Tolerance often develops with continued use
 - No therapeutic applications



Table 1.2. DEA Schedule of Controlled Substances

SCHEDULE	DESCRIPTION	EXAMPLES
I	High abuse potential (++++) No accepted medical use	heroin, LSD, MDMA (ecstasy), <i>marijuana</i>
II	High abuse potential (++++) Accepted medical use	morphine, oxycodone (OxyContin®), methamphetamine, fentanyl, Adderall®
III	Moderate abuse potential (+++) Accepted medical use	ketamine, testosterone, anabolic steroids
IV	Low abuse potential (++) Accepted medical use	Xanax®, Valium®, Ambien®, tramadol
V	Low abuse potential (+) Accepted medical use	Lyrica®, Lomotil®, many codeine-containing cough syrups



Drugs for Obesity



Obesity

- Obesity: BMI ≥ 30 kg/m² or greater
- Obesity is due in part to an energy imbalance
- Calorie consumption exceeds calorie expenditure.

- Who is a candidate for pharmacological intervention for obesity
 - BMI > 30
 - BMI > 27 with at least two comorbidities (e.g. hypertension and diabetes)

- The majority of drugs approved to treat obesity have short-term indications



Drugs for Obesity

- Anorexiant
 - Diethylpropion
 - Phentermine
- Lipase inhibitor
 - Orlistat
- GLP receptor agonists
 - Liraglutide
 - Semaglutide
- Combination products
 - Phentermine/Topiramate
 - Bupropion/naltrexone



Anorexiant

- Phentermine
- Diethylpropion
- **Mechanism of action:**
 - Phentermine increases the release of norepinephrine and dopamine and inhibits their reuptake
 - Diethylpropion has similar effects on norepinephrine
- Tolerance to the weight loss effect of these agents develops within weeks, and weight loss plateaus
- Discontinuation is usually recommended once plateau is reached



Anorexiant

- Phentermine
- Diethylpropion
- Phentermine and diethylpropion are primarily excreted via **kidneys**
- Diethylpropion undergoes extensive first-pass metabolism, many of the metabolites are active



Anorexiant

- Adverse effects:
 - All anorexiant are classified as controlled substances due to the potential for dependence or abuse.
 - Dry mouth, headache, insomnia, and constipation
 - Heart rate and blood pressure may be increased with these agents.
- Should be avoided in uncontrolled hypertension, cardiovascular disease, arrhythmias, heart failure, or stroke
- Concomitant use of anorexiants with MAOIs or other sympathomimetics should be avoided



Orlistat

- Lipase inhibitors
- Use is limited by gastrointestinal adverse effects.
- Mechanism of action:
 - Orlistat inhibits gastric and pancreatic lipases, thus decreasing the breakdown of dietary fat into smaller molecules that can be absorbed.
 - Administration of orlistat decreases fat absorption by about 30%
 - The loss of calories from decreased absorption of fat is the main cause of weight loss.
- Administered orally with each meal that contains fat
- It has minimal systemic absorption and is mainly excreted in the feces
- No dosage adjustments are required in patients with renal or hepatic dysfunction.



Orlistat

- Adverse effects:
- Gastrointestinal symptoms, such as oily spotting, flatulence with discharge, fecal urgency, and increased defecation
 - These effects may be minimized through a low-fat diet and the use of cholestyramine
- Pancreatitis and liver injury (Rare)
- Contraindicated in pregnancy and in patients with chronic malabsorption syndrome or cholestasis.
- Interferes with the absorption of fat-soluble vitamins and β -carotene



GLP 1 agonists

- Liraglutide
- Semaglutide
- Injectable glucagon-like peptide-1 (GLP-1) receptor agonists that are indicated for chronic weight management.
- GLP-1 is important in regulation of appetite and food intake, and administration of these agents reduces hunger, thereby leading to decreased caloric intake and weight loss.
- Liraglutide is dosed daily and semaglutide has a once- weekly dosing schedule.
- Also indicated for the treatment of type 2 diabetes



Combination products

- The combination of **phentermine and topiramate** has been approved for long-term use in the treatment of obesity
- Because of the sedating effects of topiramate, the stimulant phentermine was added



Phentermine and Topiramate

- The dose is escalated every 2 weeks
- If a patient does not achieve a 5% weight loss after 12 weeks on the highest dose, it should be discontinued
- Should not be stopped abruptly as seizures may be precipitated.
- Topiramate has been associated with birth defects including cleft palate
- Adverse effects
 - Paresthesias, suicidal ideation, and cognitive dysfunction
 - Increased heart rate
- Topiramate may reduce the efficacy of oral contraceptives